<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375777</url>
  </required_header>
  <id_info>
    <org_study_id>20101154</org_study_id>
    <nct_id>NCT01375777</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels</brief_title>
  <acronym>MENDEL</acronym>
  <official_title>A Randomized, Placebo- and Ezetimibe-controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10-year Framingham Risk Score of 10% or Less</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG
      145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change
      from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LDL-C was measured using ultracentrifugation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LDL-C was measured using ultracentrifugation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">411</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 10 mg ezetimibe orally once a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 70 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 105 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 140 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 280 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 350 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 420 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Evolocumab 70 mg Q2W</arm_group_label>
    <arm_group_label>Evolocumab 105 mg Q2W</arm_group_label>
    <arm_group_label>Evolocumab 140 mg Q2W</arm_group_label>
    <arm_group_label>Evolocumab 280 mg Q4W</arm_group_label>
    <arm_group_label>Evolocumab 350 mg Q4W</arm_group_label>
    <arm_group_label>Evolocumab 420 mg Q4W</arm_group_label>
    <other_name>AMG 145</other_name>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Administered orally once a day</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 75 years of age

          -  Low density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and &lt; 190 mg/dL

          -  Framingham risk score of 10% or less

          -  Fasting triglycerides &lt; 400 mg/dL

        Exclusion Criteria:

          -  History of coronary heart disease

          -  New York Heart Association (NYHA) II - IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antoio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carina Heights</city>
        <state>Queensland</state>
        <zip>4152</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>AnthÃ©e</city>
        <zip>5520</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dour</city>
        <zip>7370</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gozee</city>
        <zip>6534</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gribomont</city>
        <zip>6887</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halen</city>
        <zip>3545</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ham</city>
        <zip>3945</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linkebeek</city>
        <zip>1630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Retie</city>
        <zip>2470</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <zip>A0A 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1N 1W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granby</city>
        <state>Quebec</state>
        <zip>J2G 8Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012 Dec 8;380(9858):1995-2006. doi: 10.1016/S0140-6736(12)61771-1. Epub 2012 Nov 6.</citation>
    <PMID>23141812</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <results_first_submitted>September 3, 2015</results_first_submitted>
  <results_first_submitted_qc>September 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2015</results_first_posted>
  <disposition_first_submitted>March 26, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 2, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 9, 2013</disposition_first_posted>
  <last_update_submitted>September 3, 2015</last_update_submitted>
  <last_update_submitted_qc>September 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High cholesterol</keyword>
  <keyword>Proprotein convertase subtilisin/kexin type 9 (PCSK9)</keyword>
  <keyword>Treatment for high cholesterol</keyword>
  <keyword>Lowering cholesterol</keyword>
  <keyword>Lowering high cholesterol</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study enrolled adults 18 - 75 years with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and &lt; 190 mg/dL, fasting triglycerides ≤ 400 mg/dL and a National Cholesterol Education Program Adult Treatment Panel III Framingham risk score of 10% or less. First patient enrolled 06 July 2011, last patient enrolled 25 November 2011.</recruitment_details>
      <pre_assignment_details>Participants were randomized with equal allocation into 1 of 9 treatment groups. Randomization was stratified on the basis of screening LDL-C concentration (&lt; 130 mg/dL [3.4 mmol/L] or ≥ 130 mg/dL).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Q4W</title>
          <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Ezetimibe</title>
          <description>Participants received 10 mg ezetimibe orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Evolocumab 70 mg Q2W</title>
          <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Evolocumab 105 mg Q2W</title>
          <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Evolocumab 280 mg Q4W</title>
          <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Evolocumab 350 mg Q4W</title>
          <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="P9">
          <title>Evolocumab 420 mg Q4W</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="45"/>
                <participants group_id="P7" count="46"/>
                <participants group_id="P8" count="46"/>
                <participants group_id="P9" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="45"/>
                <participants group_id="P7" count="45"/>
                <participants group_id="P8" count="45"/>
                <participants group_id="P9" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="44"/>
                <participants group_id="P7" count="44"/>
                <participants group_id="P8" count="44"/>
                <participants group_id="P9" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (all randomized participants who received at least 1 dose of investigational product).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Q4W</title>
          <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Ezetimibe</title>
          <description>Participants received 10 mg ezetimibe orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Evolocumab 70 mg Q2W</title>
          <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Evolocumab 105 mg Q2W</title>
          <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Evolocumab 280 mg Q4W</title>
          <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Evolocumab 350 mg Q4W</title>
          <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Evolocumab 420 mg Q4W</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="45"/>
            <count group_id="B5" value="46"/>
            <count group_id="B6" value="45"/>
            <count group_id="B7" value="45"/>
            <count group_id="B8" value="45"/>
            <count group_id="B9" value="45"/>
            <count group_id="B10" value="406"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="9.8"/>
                    <measurement group_id="B2" value="50.7" spread="12.6"/>
                    <measurement group_id="B3" value="50.0" spread="12.0"/>
                    <measurement group_id="B4" value="50.9" spread="12.9"/>
                    <measurement group_id="B5" value="48.3" spread="11.8"/>
                    <measurement group_id="B6" value="52.8" spread="11.6"/>
                    <measurement group_id="B7" value="49.3" spread="10.3"/>
                    <measurement group_id="B8" value="50.9" spread="13.1"/>
                    <measurement group_id="B9" value="50.1" spread="12.0"/>
                    <measurement group_id="B10" value="50.6" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="28"/>
                    <measurement group_id="B8" value="33"/>
                    <measurement group_id="B9" value="26"/>
                    <measurement group_id="B10" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="19"/>
                    <measurement group_id="B10" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="36"/>
                    <measurement group_id="B9" value="33"/>
                    <measurement group_id="B10" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ot Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="38"/>
                    <measurement group_id="B8" value="40"/>
                    <measurement group_id="B9" value="35"/>
                    <measurement group_id="B10" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: LDL-C level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 130 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 130 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="31"/>
                    <measurement group_id="B10" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147.0" spread="21.0"/>
                    <measurement group_id="B2" value="142.3" spread="24.3"/>
                    <measurement group_id="B3" value="144.2" spread="25.8"/>
                    <measurement group_id="B4" value="143.1" spread="21.7"/>
                    <measurement group_id="B5" value="141.5" spread="22.3"/>
                    <measurement group_id="B6" value="139.8" spread="21.1"/>
                    <measurement group_id="B7" value="141.1" spread="21.8"/>
                    <measurement group_id="B8" value="136.6" spread="20.8"/>
                    <measurement group_id="B9" value="138.9" spread="21.9"/>
                    <measurement group_id="B10" value="141.6" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.8" spread="30.5"/>
                    <measurement group_id="B2" value="169.1" spread="27.7"/>
                    <measurement group_id="B3" value="170.0" spread="32.0"/>
                    <measurement group_id="B4" value="169.0" spread="24.5"/>
                    <measurement group_id="B5" value="169.2" spread="24.3"/>
                    <measurement group_id="B6" value="163.8" spread="23.7"/>
                    <measurement group_id="B7" value="166.3" spread="27.8"/>
                    <measurement group_id="B8" value="161.1" spread="26.1"/>
                    <measurement group_id="B9" value="167.9" spread="29.6"/>
                    <measurement group_id="B10" value="167.8" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111.7" spread="17.1"/>
                    <measurement group_id="B2" value="110.4" spread="17.2"/>
                    <measurement group_id="B3" value="109.9" spread="17.7"/>
                    <measurement group_id="B4" value="108.7" spread="15.7"/>
                    <measurement group_id="B5" value="108.5" spread="15.2"/>
                    <measurement group_id="B6" value="107.2" spread="16.3"/>
                    <measurement group_id="B7" value="109.2" spread="15.7"/>
                    <measurement group_id="B8" value="105.8" spread="15.9"/>
                    <measurement group_id="B9" value="110.2" spread="18.4"/>
                    <measurement group_id="B10" value="109.1" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol/HDL-C Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.477" spread="1.293"/>
                    <measurement group_id="B2" value="4.793" spread="1.836"/>
                    <measurement group_id="B3" value="4.670" spread="1.258"/>
                    <measurement group_id="B4" value="4.335" spread="1.090"/>
                    <measurement group_id="B5" value="4.571" spread="1.269"/>
                    <measurement group_id="B6" value="4.181" spread="1.131"/>
                    <measurement group_id="B7" value="4.500" spread="1.154"/>
                    <measurement group_id="B8" value="4.335" spread="1.282"/>
                    <measurement group_id="B9" value="4.741" spread="1.656"/>
                    <measurement group_id="B10" value="4.512" spread="1.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B/Apolipoprotein A-1 Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.729" spread="0.180"/>
                    <measurement group_id="B2" value="0.785" spread="0.322"/>
                    <measurement group_id="B3" value="0.752" spread="0.176"/>
                    <measurement group_id="B4" value="0.705" spread="0.161"/>
                    <measurement group_id="B5" value="0.744" spread="0.168"/>
                    <measurement group_id="B6" value="0.709" spread="0.175"/>
                    <measurement group_id="B7" value="0.751" spread="0.161"/>
                    <measurement group_id="B8" value="0.706" spread="0.185"/>
                    <measurement group_id="B9" value="0.758" spread="0.191"/>
                    <measurement group_id="B10" value="0.738" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <description>LDL-C was measured using ultracentrifugation.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing ultracentrifugation (UC) LDL-C at Week 12 was imputed using last observation carried forward (LOCF) and calculated LDL-C.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe</title>
            <description>Participants received 10 mg ezetimibe orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <description>LDL-C was measured using ultracentrifugation.</description>
          <population>Full analysis set; missing ultracentrifugation (UC) LDL-C at Week 12 was imputed using last observation carried forward (LOCF) and calculated LDL-C.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="45"/>
                <count group_id="O9" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.71" spread="2.66"/>
                    <measurement group_id="O2" value="4.54" spread="2.64"/>
                    <measurement group_id="O3" value="-14.26" spread="2.60"/>
                    <measurement group_id="O4" value="-40.98" spread="2.64"/>
                    <measurement group_id="O5" value="-43.87" spread="2.60"/>
                    <measurement group_id="O6" value="-50.93" spread="2.66"/>
                    <measurement group_id="O7" value="-39.02" spread="2.57"/>
                    <measurement group_id="O8" value="-43.20" spread="2.57"/>
                    <measurement group_id="O9" value="-47.98" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.52</ci_lower_limit>
            <ci_upper_limit>-39.93</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-47.38</ci_lower_limit>
            <ci_upper_limit>-32.95</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.53</ci_lower_limit>
            <ci_upper_limit>-30.02</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.67</ci_lower_limit>
            <ci_upper_limit>-45.38</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.89</ci_lower_limit>
            <ci_upper_limit>-40.60</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-43.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.71</ci_lower_limit>
            <ci_upper_limit>-36.42</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Week 12</title>
        <description>LDL-C was measured using ultracentrifugation.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing ultracentrifugation (UC) LDL-C at Week 12 was imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe</title>
            <description>Participants received 10 mg ezetimibe orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Week 12</title>
          <description>LDL-C was measured using ultracentrifugation.</description>
          <population>Full analysis set; missing ultracentrifugation (UC) LDL-C at Week 12 was imputed using LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="45"/>
                <count group_id="O9" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="3.9"/>
                    <measurement group_id="O2" value="7.3" spread="3.7"/>
                    <measurement group_id="O3" value="-19.2" spread="3.6"/>
                    <measurement group_id="O4" value="-55.7" spread="3.7"/>
                    <measurement group_id="O5" value="-66.0" spread="3.7"/>
                    <measurement group_id="O6" value="-69.3" spread="3.6"/>
                    <measurement group_id="O7" value="-53.5" spread="3.6"/>
                    <measurement group_id="O8" value="-56.7" spread="3.6"/>
                    <measurement group_id="O9" value="-65.0" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-65.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-76.3</ci_lower_limit>
            <ci_upper_limit>-55.6</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-62.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-73.2</ci_lower_limit>
            <ci_upper_limit>-52.2</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.7</ci_lower_limit>
            <ci_upper_limit>-41.9</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-72.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-82.2</ci_lower_limit>
            <ci_upper_limit>-62.4</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-63.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.9</ci_lower_limit>
            <ci_upper_limit>-54.0</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.7</ci_lower_limit>
            <ci_upper_limit>-50.9</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe</title>
            <description>Participants received 10 mg ezetimibe orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12</title>
          <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="45"/>
                <count group_id="O9" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="2.40"/>
                    <measurement group_id="O2" value="-0.25" spread="2.30"/>
                    <measurement group_id="O3" value="-15.53" spread="2.36"/>
                    <measurement group_id="O4" value="-37.95" spread="2.38"/>
                    <measurement group_id="O5" value="-39.68" spread="2.34"/>
                    <measurement group_id="O6" value="-48.04" spread="2.40"/>
                    <measurement group_id="O7" value="-37.94" spread="2.24"/>
                    <measurement group_id="O8" value="-42.14" spread="2.24"/>
                    <measurement group_id="O9" value="-47.36" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.72</ci_lower_limit>
            <ci_upper_limit>-38.58</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-43.29</ci_lower_limit>
            <ci_upper_limit>-30.29</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.59</ci_lower_limit>
            <ci_upper_limit>-28.52</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.33</ci_lower_limit>
            <ci_upper_limit>-40.89</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-41.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.11</ci_lower_limit>
            <ci_upper_limit>-35.67</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.92</ci_lower_limit>
            <ci_upper_limit>-31.47</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe</title>
            <description>Participants received 10 mg ezetimibe orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
          <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="45"/>
                <count group_id="O9" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="2.28"/>
                    <measurement group_id="O2" value="0.19" spread="2.28"/>
                    <measurement group_id="O3" value="-11.17" spread="2.19"/>
                    <measurement group_id="O4" value="-32.66" spread="2.26"/>
                    <measurement group_id="O5" value="-36.20" spread="2.23"/>
                    <measurement group_id="O6" value="-44.52" spread="2.28"/>
                    <measurement group_id="O7" value="-33.04" spread="2.21"/>
                    <measurement group_id="O8" value="-37.73" spread="2.21"/>
                    <measurement group_id="O9" value="-42.29" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-44.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.45</ci_lower_limit>
            <ci_upper_limit>-37.94</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-35.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-42.06</ci_lower_limit>
            <ci_upper_limit>-29.69</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.55</ci_lower_limit>
            <ci_upper_limit>-26.11</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-42.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.63</ci_lower_limit>
            <ci_upper_limit>-36.32</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.07</ci_lower_limit>
            <ci_upper_limit>-31.76</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-33.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.38</ci_lower_limit>
            <ci_upper_limit>-27.07</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe</title>
            <description>Participants received 10 mg ezetimibe orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12</title>
          <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="45"/>
                <count group_id="O9" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="2.17"/>
                    <measurement group_id="O2" value="-3.39" spread="2.11"/>
                    <measurement group_id="O3" value="-16.65" spread="1.99"/>
                    <measurement group_id="O4" value="-30.07" spread="2.15"/>
                    <measurement group_id="O5" value="-33.13" spread="2.12"/>
                    <measurement group_id="O6" value="-38.70" spread="2.17"/>
                    <measurement group_id="O7" value="-32.07" spread="2.05"/>
                    <measurement group_id="O8" value="-34.60" spread="2.05"/>
                    <measurement group_id="O9" value="-39.97" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.43</ci_lower_limit>
            <ci_upper_limit>-31.54</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-31.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-37.79</ci_lower_limit>
            <ci_upper_limit>-26.04</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.77</ci_lower_limit>
            <ci_upper_limit>-22.95</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.29</ci_lower_limit>
            <ci_upper_limit>-30.88</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-31.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.92</ci_lower_limit>
            <ci_upper_limit>-25.51</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.39</ci_lower_limit>
            <ci_upper_limit>-22.98</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe</title>
            <description>Participants received 10 mg ezetimibe orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 105 mg Q2W</title>
            <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Evolocumab 350 mg Q4W</title>
            <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12</title>
          <population>Full analysis set; missing data at Week 12 were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="45"/>
                <count group_id="O9" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="2.40"/>
                    <measurement group_id="O2" value="0.14" spread="2.46"/>
                    <measurement group_id="O3" value="-12.35" spread="2.33"/>
                    <measurement group_id="O4" value="-32.80" spread="2.38"/>
                    <measurement group_id="O5" value="-38.30" spread="2.35"/>
                    <measurement group_id="O6" value="-48.13" spread="2.40"/>
                    <measurement group_id="O7" value="-36.10" spread="2.39"/>
                    <measurement group_id="O8" value="-40.43" spread="2.39"/>
                    <measurement group_id="O9" value="-45.33" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-50.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.75</ci_lower_limit>
            <ci_upper_limit>-43.58</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-46.84</ci_lower_limit>
            <ci_upper_limit>-33.82</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.38</ci_lower_limit>
            <ci_upper_limit>-28.28</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.12</ci_lower_limit>
            <ci_upper_limit>-38.82</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-40.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.22</ci_lower_limit>
            <ci_upper_limit>-33.92</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and the stratification factor.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.90</ci_lower_limit>
            <ci_upper_limit>-29.60</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Q4W</title>
          <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Ezetimibe</title>
          <description>Participants received 10 mg ezetimibe orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Evolocumab 70 mg Q2W</title>
          <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Evolocumab 105 mg Q2W</title>
          <description>Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Evolocumab 280 mg Q4W</title>
          <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Evolocumab 350 mg Q4W</title>
          <description>Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Evolocumab 420 mg Q4W</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

